PT3534902T - Combinações de inibidores de fgfr4 e quelantes de ácidos biliares - Google Patents

Combinações de inibidores de fgfr4 e quelantes de ácidos biliares

Info

Publication number
PT3534902T
PT3534902T PT178122693T PT17812269T PT3534902T PT 3534902 T PT3534902 T PT 3534902T PT 178122693 T PT178122693 T PT 178122693T PT 17812269 T PT17812269 T PT 17812269T PT 3534902 T PT3534902 T PT 3534902T
Authority
PT
Portugal
Prior art keywords
combinations
bile acid
acid sequestrants
fgfr4 inhibitors
fgfr4
Prior art date
Application number
PT178122693T
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT3534902T publication Critical patent/PT3534902T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT178122693T 2016-11-02 2017-11-01 Combinações de inibidores de fgfr4 e quelantes de ácidos biliares PT3534902T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662416222P 2016-11-02 2016-11-02

Publications (1)

Publication Number Publication Date
PT3534902T true PT3534902T (pt) 2022-12-07

Family

ID=60661908

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178122693T PT3534902T (pt) 2016-11-02 2017-11-01 Combinações de inibidores de fgfr4 e quelantes de ácidos biliares

Country Status (18)

Country Link
US (1) US11229643B2 (pt)
EP (1) EP3534902B1 (pt)
JP (2) JP7394623B2 (pt)
KR (1) KR102362648B1 (pt)
CN (2) CN117257800A (pt)
AU (1) AU2017354082B2 (pt)
BR (1) BR112019008787A2 (pt)
CA (1) CA3042475C (pt)
ES (1) ES2934341T3 (pt)
IL (1) IL266293B (pt)
MA (1) MA46712A (pt)
MX (1) MX2019005194A (pt)
PL (1) PL3534902T3 (pt)
PT (1) PT3534902T (pt)
RU (1) RU2742033C2 (pt)
SG (1) SG11201903911UA (pt)
WO (1) WO2018083603A1 (pt)
ZA (1) ZA201902744B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054483A1 (en) 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
CN112759593A (zh) * 2019-11-01 2021-05-07 北京伯汇生物技术有限公司 桥环并醛基吡啶衍生物及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007136893A2 (en) 2006-02-10 2007-11-29 Genentech, Inc. Anti-fgf19 antibodies and methods using same
EP1918376A1 (en) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
US9205094B2 (en) * 2006-12-22 2015-12-08 Ironwood Pharmaceuticals, Inc. Compositions comprising bile acid sequestrants for treating esophageal disorders
PE20090227A1 (es) 2007-04-02 2009-04-03 Genentech Inc Composiciones farmaceuticas que comprenden agentes anti-beta-klotho
US8524212B2 (en) 2007-10-24 2013-09-03 Mitsubishi Tanabe Pharma Corporation Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
US20110212091A1 (en) 2008-09-03 2011-09-01 Licentia Ltd. Materials and methods for inhibiting cancer cell invasion
US20100330175A1 (en) 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
KR20140021589A (ko) 2011-04-07 2014-02-20 제넨테크, 인크. 항-fgfr4 항체 및 사용 방법
CN104053449B (zh) 2011-08-17 2016-12-07 硬木药品公司 胃肠疾患的治疗
WO2014011900A2 (en) 2012-07-11 2014-01-16 Blueprint Medicines Inhibitors of the fibroblast growth factor receptor
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods of regulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014105849A1 (en) 2012-12-28 2014-07-03 Xoma (Us) Llc Antibodies specific for fgfr4 and methods of use
WO2014165287A1 (en) 2013-03-12 2014-10-09 The Translational Genomics Research Institute Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4
PE20151776A1 (es) 2013-03-15 2015-12-11 Celgene Avilomics Res Inc Compuestos de heteroarilo y sus usos
US9676792B2 (en) 2013-03-15 2017-06-13 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
AR097455A1 (es) 2013-08-28 2016-03-16 Astellas Pharma Inc Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo
BR112016008110B1 (pt) 2013-10-18 2019-07-02 Eisai R&D Management Co., Ltd. Composto inibidor de pirimidina fgfr4, composição farmacêutica compreendendo dito compoto e usos terapêuticos destes
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
WO2015107171A1 (en) 2014-01-17 2015-07-23 Sanofi Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-fgfr4 antibody
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
PL3180356T3 (pl) 2014-08-11 2020-04-30 Daiichi Sankyo Europe Gmbh Ludzkie przeciwciało anty-fgfr4
WO2016054483A1 (en) 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
WO2016064960A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN107438607B (zh) 2015-02-20 2021-02-05 因赛特公司 作为fgfr抑制剂的双环杂环
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN107787226A (zh) * 2015-03-25 2018-03-09 诺华股份有限公司 药物组合
EP3095465A1 (en) * 2015-05-19 2016-11-23 U3 Pharma GmbH Combination of fgfr4-inhibitor and bile acid sequestrant

Also Published As

Publication number Publication date
KR102362648B1 (ko) 2022-02-11
ES2934341T3 (es) 2023-02-21
CN109922804A (zh) 2019-06-21
CA3042475C (en) 2024-01-16
CN109922804B (zh) 2023-11-17
IL266293A (en) 2019-06-30
JP2022033766A (ja) 2022-03-02
CN117257800A (zh) 2023-12-22
RU2019116061A3 (pt) 2020-12-04
RU2019116061A (ru) 2020-12-04
EP3534902A1 (en) 2019-09-11
JP2019533701A (ja) 2019-11-21
RU2742033C2 (ru) 2021-02-01
WO2018083603A1 (en) 2018-05-11
ZA201902744B (en) 2021-08-25
CA3042475A1 (en) 2018-05-11
AU2017354082B2 (en) 2023-07-27
JP7394623B2 (ja) 2023-12-08
PL3534902T3 (pl) 2023-03-27
BR112019008787A2 (pt) 2019-07-16
SG11201903911UA (en) 2019-05-30
AU2017354082A1 (en) 2019-05-23
US11229643B2 (en) 2022-01-25
US20200261444A1 (en) 2020-08-20
MA46712A (fr) 2019-09-11
IL266293B (en) 2022-07-01
MX2019005194A (es) 2019-08-05
KR20190082256A (ko) 2019-07-09
EP3534902B1 (en) 2022-11-23

Similar Documents

Publication Publication Date Title
HK1259232A1 (zh) Menin-mll的取代抑制劑及其使用方法
ZA201707981B (en) Compositions of obeticholic acid and methods of use
HK1246286A1 (zh) Lrrk2抑制劑及其製備和使用方法
HK1243930A1 (zh) 作爲fxr/tgr5激動劑的膽汁酸類似物和其使用方法
HK1244708A1 (zh) 作爲fxr/tgr5激動劑的胆汁酸類似物及其使用方法
HK1250622A1 (zh) 作為fxr/tgr5激動劑的膽汁酸衍生物及其使用方法
HK1245100A1 (zh) 作為fxr/tgr5激動劑的膽汁酸類似物及其使用方法
EP3209815A4 (en) Corrosion inhibitors and related compositions and methods
IL249223A0 (en) Mth1 inhibitors for the treatment of inflammatory and autoimmune conditions
IL256671A (en) System and method of assessing endothelial function
IL259796A (en) Aza-benzimidazole inhibitors of pad4
HK1246690A1 (zh) 用於鑒定高度特異性核酸酶的方法和組合物
EP3373981A4 (en) IDENTIFICATION AND CHARACTERIZATION OF NOVEL CORROSION INHIBITOR MOLECULES
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
HK1257171A1 (zh) 間變性淋巴瘤激酶(alk)和絲氨酸富集蛋白激酶 (sppk)的抑制劑及其使用方法
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
ZA201902744B (en) Combinations of fgfr4 inhibitors and bile acid sequestrants
GB201417081D0 (en) System for and method of determining corrosion risks
EP3268011A4 (en) INHIBITORS OF THE DEK PROTEIN AND RELATED METHODS
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
DK3180814T3 (da) Phytinsyrebaseret metallogel og anvendelser deraf
GB201701719D0 (en) Method of assessing risk
SG10201408714QA (en) Point of sale system and method
EP3231897A4 (en) Biological metal corrosion inhibitor and use thereof
GB201601843D0 (en) Method of assessing risk